Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core

2017 ◽  
Vol 17 (27) ◽  
Author(s):  
Hongzhi Lin ◽  
Qi Li ◽  
Kai Gu ◽  
Jie Zhu ◽  
Xueyang Jiang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Recent Progress ◽  
Therapeutic Agents

scholarly journals Platinum-based inhibitors of amyloid-  as therapeutic agents for Alzheimer's disease

2008 ◽  
Vol 105 (19) ◽  
pp. 6813-6818 ◽  
Author(s):  
K. J. Barnham ◽  
V. B. Kenche ◽  
G. D. Ciccotosto ◽  
D. P. Smith ◽  
D. J. Tew ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents

scholarly journals Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease

2017 ◽  
Vol 8 (8) ◽  
pp. 5636-5643 ◽  
Author(s):  
Michael R. Jones ◽  
Emilie Mathieu ◽  
Christine Dyrager ◽  
Simon Faissner ◽  
Zavier Vaillancourt ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents ◽  
Peptide Aggregation ◽  
Primary Neurons ◽  
Aβ Peptide

A series of multi-target-directed ligands are described that bind Cu, act as antioxidants, modulate Aβ peptide aggregation, and abolish Aβ toxicity in primary neurons.

The olfactory system in Alzheimer’s disease: Pathology, pathophysiology and pathway for therapy

2013 ◽  
Vol 4 (1) ◽  
Author(s):  
Tibor Kovács
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Side Effects ◽  
Olfactory System ◽  
Therapeutic Agents ◽  
Non Invasive ◽  
Degenerative Disorders ◽  
Invasive Method

AbstractOlfaction is frequently mentioned as a “neglected sense”, although the olfactory system has several interesting and unique anatomical and physiological features. Olfactory involvement is present in several degenerative disorders, especially in Alzheimer’s disease (AD). The peripheral and central parts of the olfactory system are damaged even in the early stages of AD, manifesting in profound olfactory deficits. Besides the early pathology, the olfactory system may be involved in the pathogenesis of AD by providing a route of entry for pathological agents still unknown. In contrast to this olfactory vector hypothesis, the olfactory system can be used to deliver therapeutic agents in AD, such as nerve growth factor and insulin, by decreasing the side-effects of the therapy or providing a non-invasive method of delivery.

Sign in / Sign up

Export Citation Format

Share Document